*8-Feb-2012* *HYDERABAD* : Hyderabad-based biopharmaceutical company Suven Life Sciences Limited (Suven) stated that it has secured three patents, two from the US and one from Mexico, for its new chemical entities (NCEs) for the treatment of disorders associated with neuro-degenerative diseases. These patents are valid through 2025 and 2028.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents that are useful in the treatment of cognitive impairment associated with disorders like Alzheimer’s disease, attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia. With the new patents, Suven has a total of 11 patents from the US and 12 patents from Mexico. “We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the central nervous system (CNS) arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally,” chief executive officer of the company, Venkat Jasti, stated in a press release on Tuesday. http://www.business-standard.com/india/printpage.php?autono=463976&tp= -- You received this message because you are subscribed to the Google Groups "Mental Health Advocacy (News 'N Views) India" group. To post to this group, send email to [email protected] To unsubscribe from this group, send email to [email protected] For more options, visit this group at http://groups.google.com/group/MhaNewsViewsIndia?hl=en ------------- Affiliated Groups : MENTAL HEALTH ADVOCACY INDIA [email protected] Discussions on mental health law / policy / plan monitoring / human rights etc [email protected] India-specific news and views related to mental health [email protected] Information and support to carers of people with mental health issues [email protected] Mutual support and sharing of experiential knowledge, skills and social learning amongst peers
